The concept that frequent ARID2 mutations are influencing the immune checkpoint inhibitors, being correlated to increased CD8+ T cells, supports the role of ARID2 as a potential biomarker of therapeutic efficiency of immune checkpoint inhibitors in patients with melanoma [68]. The gene discussed is ARID2; the disease is melanoma.